This New Blood Test Can Detect Alzheimer’s Dementia With 93% Accuracy

According to the Alzheimer’s Association, more than 6 million Americans are living with the disease. The condition is appalling, and it gets worse when it reaches the dementia stage.

A new blood test may be able to identify people at risk of developing the disease early on allowing them to get the necessary help. The press release was published by the Washington University School of Medicine in St. Louis. 

“Our study shows that the blood test provides a robust measure for detecting amyloid plaques associated with Alzheimer’s disease, even among patients not yet experiencing cognitive declines,” said in the statement senior author Randall J. Bateman, MD, the Charles F., and Joanne Knight Distinguished Professor of Neurology.

New Blood Test Catches Alzheimer's Early, Helps Find A Cure

“A blood test for Alzheimer’s provides a huge boost for Alzheimer’s research and diagnosis, drastically cutting the time and cost of identifying patients for clinical trials and spurring the development of new treatment options,” Bateman added. “As new drugs become available, a blood test could determine who might benefit from treatment, including those at very early stages of the disease.”

In a study involving almost 500 patients from the United States, Australia, and Sweden, the new blood test proved 93 percent accuracy. This can prove to be revolutionary.

Blood test for Alzheimer's proves highly accurate in large, international  study

Currently, PET brain scans are used by researchers to identify the disease. These come with an average cost of $5,000 to $8,000 per scan. It can also be done through a spinal tap test which costs only about $1,000 but comprises a procedure that most patients do not want to go through.

The new blood test would only cost $500 and could be completed in less than six months. Research states that the test remains highly accurate regardless of the labs it is performed in or the protocols which are followed.

“These results suggest the test can be useful in identifying nonimpaired patients who may be at risk for future dementia, offering them the opportunity to get enrolled in clinical trials when early intervention has the potential to do the best,” Bateman concluded.

Leave a Reply

Your email address will not be published. Required fields are marked *